

## CRITICAL REVIEW

# Status of epilepsy in the tropics: An overlooked perspective

Jiaqi Liu<sup>1,2</sup>  | Peng Zhang<sup>1,2,3</sup> | Qin Zou<sup>4</sup> | Jiantang Liang<sup>1,2</sup> | Yongmin Chen<sup>5</sup> | Yi Cai<sup>1</sup> | Shichuo Li<sup>6</sup>  | Jinmei Li<sup>7</sup>  | Jing Su<sup>1</sup> | Qifu Li<sup>1,2</sup>

<sup>1</sup>Department of Neurology, the First Affiliated Hospital, International School of Public Health and One Health, Hainan Medical University, Haikou, China

<sup>2</sup>Hainan Provincial Key Laboratory of Tropical Brain Research and Transformation, Hainan Medical University, Haikou, China

<sup>3</sup>Department of Forensic Medicine, Hainan Medical University, Haikou, China

<sup>4</sup>Department of Medical Psychology, The First Affiliated Hospital of Hainan Medical University, Haikou, China

<sup>5</sup>Department of Functional Diagnosis, The Second Affiliated Hospital of Hainan Medical University, Haikou, China

<sup>6</sup>China Association Against Epilepsy, Beijing, China

<sup>7</sup>Department of Neurology, West China Hospital of Sichuan University, Chengdu, China

## Correspondence

Jinmei Li, Department of Neurology, West China Hospital of Sichuan University, Chengdu, 610041, China.  
Email: [ljjinmei@wchsc.cn](mailto:ljjinmei@wchsc.cn)

Jing Su, International School of Public Health and Whole Health, Hainan Medical University, Haikou, 571199, China.  
Email: [smiles.j.su@hainmc.edu.cn](mailto:smiles.j.su@hainmc.edu.cn)

Qifu Li, Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou, 570100, China, and Hainan Provincial Key Laboratory of Tropical Brain Research and Transformation, Hainan Medical University, Haikou, 570000, China.  
Email: [lee-chief@163.com](mailto:lee-chief@163.com)

## Funding information

Hainan Province Clinical Medical Center(2021) and the Excellent Talent Team of Hainan Province, Grant/Award Number: QRCBT202121; National Natural Science Foundation of China, Grant/Award Number: 81960249 and 82260270; Key Research and Development Project of Hainan Province, Grant/Award

## Abstract

Epilepsy is one of the most common serious chronic neurological diseases affecting people of all ages globally. It is characterized by recurrent seizures. About 50 million people worldwide have epilepsy. Indubitably, people with epilepsy (PWE) may be without access to appropriate treatment. Many studies have examined the molecular mechanisms and clinical aspects of epilepsy; nonetheless, the treatment gap exists in some special areas. In the tropics, the specific geographical and ecological conditions and a lack of medical resources result in neglect or delay of diagnosis for PWE. Herein, we summarized the epidemiology of epilepsy in the tropics and discussed the disease burden and existing problems, aiming to offer a medical environment for patients in need and highlight the importance of reducing the epileptic disease burden in tropical countries.

## KEYWORDS

disease burden, disease status, epidemiology, epilepsy, tropics

Jiaqi Liu, Peng Zhang, Qin Zou authors contributed equally to this work.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *Epilepsia Open* published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Number: ZDYF2021SHFZ092 and ZDYF2022SHFZ109; Natural Science Foundation of Hainan Province, Grant/Award Number: 822RC832; Hainan Medical University

## 1 | INTRODUCTION

The tropics, a zone between the Tropic of Cancer and the Tropic of Capricorn, lies on both sides of the equator between 23°26' north and south latitude. Globally, this area includes most of Asia (parts of China, Vietnam, Laos, and other 16 countries), Oceania (south-central Australia and New Zealand), Africa (north African countries and South Africa), and Latin America (Argentina, most of Chile, and northern Mexico), accounting for 39.8% of the global territory (Figure 1). Currently, no obvious temperature variations were detected in this area, which was characterized by a seasonless state accompanied by scorching weather all year round. Despite its abundant ecological resources and biodiversity, the high humidity and sunshine throughout the year increase the range and prolong the cycle of mosquito vectors. Moreover, the social-economic status of this area was low. However, only a few studies have focused on epilepsy pathogens in the tropics. The lack of medical resources and policy support is largely responsible for the fact that the people with epilepsy (PWE) in this area did not receive any necessary medical treatments. Hence, neglecting the unique pathogenic environmental factor in the tropics can lead to health disparities between this and other areas.

Among the chronic diseases that can significantly impact patients' everyday life, epilepsy is a nervous system disease caused by sudden abnormal firing of neurons, resulting in temporary brain dysfunction. The disease is characterized by repeated attacks and complex clinical manifestations. According to the latest ILAE classification of the epilepsies in 2017, epilepsy seizures can be classified into "focal onset," "generalized onset," and "unknown onset." The primary presenting symptoms can manifest as individual or combined clinical signs, including "consciousness disorder," "myoclonus," "absence," and "other motor-related disorders."<sup>1,2</sup> Remarkably, the number of patients accompanied by varying psychological disorders has increased substantially over recent years. Previous studies have shown that cognitive dysfunction, anxiety, and depression are common comorbidities among patients with epilepsy, with prevalence rates much higher than in healthy people (30%-40%, 20%-40%, and 20%-60%, respectively).<sup>3,4</sup> Furthermore, different aspects of quality of life (QoL), including physical health, cognitive function, psychological or psychic disorder, and

### Key Points

- Epilepsy has been one of the major public health problems worldwide, but PWE in tropical areas is ignored invariably.
- The incidence and prevalence of epilepsy are high in tropical regions, while all-sided data are still lacking, especially in Oceania.
- Multifaceted factors lead to a large treatment gap in tropical areas. Simultaneously, comorbidity and stigma accompanied by epilepsy should be taken seriously.
- The status quo of epilepsy in tropical areas can be improved by multi-party cooperation to provide medical resources, an environment for PWE, and a quality of life.

social function, can also be reduced due to this condition (Figure 2). Although this disease is harmful to patients' physical and mental health, it could affect their normal life significantly. Since the prevalence and incidence rate of epilepsy is high in low- and middle-income countries and patients with epilepsy in these countries are reluctant to seek treatment, a heavy disease burden in this area is a logical occurrence.

Currently, there are several studies on PWE. Researchers have taken different approaches, such as focusing on patients with different cultural and family backgrounds,<sup>5-7</sup> different ages,<sup>8-13</sup> region-specific,<sup>14-22</sup> and inter-environmental.<sup>23-25</sup> Some studies have focused on the treatment gap,<sup>26-30</sup> special etiology,<sup>31-36</sup> and disease burden<sup>37-40</sup> in the tropics, aiming to formulate appropriate policies<sup>41-44</sup> for PWE.

Most of these studies have focused on sub-Saharan Africa (SSA). Together, relevant data for some tropical countries are missing, and there is missing comprehensive evidence for the status of epilepsy in the tropics. Therefore, in this article, we reviewed the status quo of epilepsy in the tropics from an epidemiological aspect, disease status, and burden, and identified the risk factors, challenges, and interventions to offer an improved medical environment for patients in need and provide valuable ideas for reducing the burden of epilepsy at the global level.




FIGURE 1 Distribution diagram of tropical regions and countries

## 2 | ABOUT TROPICAL EPILEPSY

The incidence and prevalence of epilepsy in the majority of tropical countries or regions are persistent at a high level (Table 1).

Compared to other tropical areas, Asian countries show a lower rate of prevalence and incidence. China has the largest population in Asia. Take Hainan as an example; the prevalence and incidence of epilepsy in rural areas are lower than that in other tropical areas of the world.<sup>16</sup> Interestingly, an epidemiological survey of epilepsy in rural areas and ethnic minority areas in China showed a variable prevalence rate among different ethnic groups. Among them, the Bai nationality (living in Yunnan province) has a higher average prevalence rate than the Han nationality, while the Li nationality (living in Hainan Province) has a lower prevalence rate than the Han type.<sup>60</sup> This finding suggested that additional factors could be worth exploring the influence of variation in the epidemiological data for epilepsy.


### 2.1 | Epidemiology

According to the 2015 Global Burden of Disease (GBD) study, epilepsy accounted for 0.5% of all disability-adjusted life years (DALY) and 5.0% of neurological diseases DALY. On June 20, 2019, World Health Organization (WHO) Fact Sheet reported that epilepsy accounted for 0.6% of the global disease burden. A previous study assessed the burden of epilepsy in 195 countries and territories

between 1990 and 2016 and showed the dissimilarity in age-standardized disability-adjusted annual rates between countries in the lower and higher sociodemographic index (SDI) quintiles. These differences were attributed to high levels of epilepsy in about one-third of the cases in low-income countries.<sup>72</sup> More than 50 million people worldwide have epilepsy, and the number continues to increase at a rate of 2.4 million annually.<sup>73</sup> Approximately 80% of these patients live in low- or middle-income countries, and 75% did not receive timely treatment. However, the low economic level of most tropical countries is poorly reflected in the medical conditions of these regions. Due to the social conditions attributed to these economic disadvantages that affect education, science, and technology, PWE lacks an understanding of the disease and medical concepts, such as early detection, diagnosis, and treatment. Moreover, due to the lack of medical resources in many tropical countries or regions, there is also a lack of medical facilities. In addition, the psychological problems accompanying PWE are rarely given any attention, resulting in a higher incidence of epilepsy in these areas than in other parts, and most PWEs fail to receive the deserved attention.

### 2.2 | Disease status and burden

According to the available statistics, >85% of the global burden of epilepsy affects 49% of the population living in low- and middle-income countries.<sup>74</sup> The incidence and mortality rates of epilepsy are significantly high in these



**FIGURE 2** Life quality of epilepsy patients. Epilepsy can make a vital impact on PWE. For physical health, impairment of physical function is usually accompanied by the progression of epilepsy. Generally, apnea caused by epileptic seizure or symptoms including vertigo and nausea resulting in cerebral hypoxia is a common clinical manifestation. Besides, active or passive accident harm also could happen on PWE, even lose their self-care ability to an extent. For psychological/psychic disorders, PWE usually has a deep sense of isolation as for their random seizure. Meanwhile, comorbidity such as depression and anxiety is also worth taking seriously, which is sometimes ignored. For cognitive function, impairment of memory and attention dropped happens commonly among PWE, which could manifest as forgetfulness in adults and poor academic performance in children. For social function, the epileptic seizure could keep PWE away from normal social contact and the opportunity to accept education, which even leads to a rising unemployment rate among PWE. Put it another way, social dysfunction is also the result of the combined effects of the above factors, which affect the QoL among PWE from lots of perspectives

countries,<sup>75</sup> suggesting that economic levels influence the burden of epilepsy. However, as the economic level of most of the tropical countries is low, there is a shortage of medical resources with a lack of education and understanding and arrested development of the social and cultural environment, which negatively affects the prevention of epilepsy in tropical areas and the diagnosis and treatment of PWE. Eventually, this increases the burden of epilepsy in these countries and regions, causing a substantial decline in the quality of life of PWE. Therefore, this global health problem should not be ignored.

In Africa, about 10 million people are directly affected by epilepsy, accounting for 20% of PWE worldwide.<sup>76</sup> Previous studies have shown that the incidence of epilepsy in tropical SSA is 63–158/100000 people/year, and about 80% of these patients do not receive the required

treatment. Concurrently, the rate of injuries due to uncontrolled seizures is extremely high, especially burns and fatal injuries, which are six times higher in this area than in the normal control group.<sup>77</sup>

In Latin America, about 5 million people have epilepsy, of which 3 million do not receive appropriate treatment.<sup>78</sup> The disease burden of epilepsy in Latin America is approximately 14460845 DALYs (95% CI: 2.3–0.8 × 10<sup>6</sup>), with years lived with disability (YLDs) as the major component. Mexico, Brazil, and Colombia have the highest rates of epilepsy, with alcohol abuse as the main risk factor.<sup>37</sup> Thus, epilepsy remains a major cause of disability in Latin America.

In Cambodia, about 86000 people suffer from epilepsy. Unlike in Africa, people in Cambodia do not share any religious beliefs that would oppose the treatment, and hence

**TABLE 1** Incidence and prevalence of epilepsy in the majority of the tropics. In comparison, Asia and Africa show more data related to the status of PWE and the treatment gap of epilepsy in those areas. While Latin America is inferior in this respect, which mainly manifested as a lack of latest data. More seriously, there is an enormous blank in Oceania, which reflects severe neglect of PWE in this area. Compared Asia to Africa, the incidence and prevalence rate in Asia are generally lower than in Africa. We consider factors such as economic level, cultural background, resource scarcity, etc., to prompt this disparity to an extent. In Africa, Ethiopia and Nigeria showed a low prevalence rate in recent years, which is about 5.20%(2021) and 4.30%(2015) respectively. But in Rwanda, the prevalence rate was even as high as 49% in 2005. While in Asia, most of the countries had lower incidence and prevalence rates universally. What's more, there has been no significant fluctuation among the data in the table, which highlights the concern about the status quo of tropical epilepsy particularly

Continent	Country/province	Year	Incidence rate (cases/100000-year)	Prevalence rate(‰)	References
<b>Global</b>	—	2019	61.44	7.6	WHO. <sup>45</sup>
<b>Africa</b>	Burkina Faso	2015	123	12.46	Fawi G, et al. <sup>46</sup>
	Tanzania	2009	81	11.20	Winkler, et al. <sup>47</sup>
	Ethiopia	1997	64	—	Tekle-Haimanot, et al. <sup>48</sup>
		2021	—	5.20	Yazie TS, et al. <sup>49</sup>
	Benin	2013	69	12.70	Houinato, et al. <sup>50</sup>
	Kenya	2015	46	—	Kariuki, et al. <sup>51</sup>
	Zambia	2004	—	13.20	Birbeck, et al. <sup>52</sup>
	Nigeria	2015	—	4.30	Nwani, et al. <sup>53</sup>
	Rwanda	2005	—	49.00	Dedeken P, et al. <sup>54</sup>
<b>Asia</b>	India	2002	38-49	5.00	Ray BK, et al. <sup>55</sup>
	Hong Kong, China	2003	—	1.50	Fong GC, et al. <sup>56</sup>
	Taiwan, China	2007	72	6.94	Chou IJ, et al. <sup>57</sup>
		2015	54	6.86	
	Hainan, China	2021	24	3.06	Zheng GX, et al. <sup>16</sup>
	Yunnan, China	2008	18.9	1.51	Yu Z, et al. <sup>58</sup>
		2017	—	2.10-7.30	Yu Z, et al. <sup>59</sup>
	Guangdong, China	1985	49.04	—	Yang LC, et al. <sup>60</sup>
	Singapore	1997	—	5.00	Loh NK, et al. <sup>61</sup>
	Laos	2006	—	7.70	Tran DS, et al. <sup>62</sup>
	Thailand	2002	—	7.20	Asawavichienjinda T, et al. <sup>63</sup>
<b>Latin America</b>	Chile	1988	—	17.70	Hun C, et al. <sup>64</sup>
		1992	113	—	Lavados J, et al. <sup>65</sup>
	Ecuador	1992	122-190	—	Placencia M, et al. <sup>66</sup>
		Martinique	1995	87-102	—
	Honduras	1999	78	—	Jallon P, et al. <sup>68</sup>
		2003	—	5.41	Medina MT, et al. <sup>69</sup>
	Panama	2005	93	—	Medina MT, et al. <sup>70</sup>
		1986	22	—	Gracia, et al. <sup>71</sup>
	1990	57	---		

there is almost no obstacle to diagnosing and treating epilepsy in terms of ideology. Moreover, the social environment in Cambodia is more welcoming to PWE than in Africa. As a result, most Cambodians with epilepsy receive good social support and are not discriminated against or treated differently because of their condition.<sup>79</sup> In addition, differences are observed in the treatment gap of epilepsy across several countries in Asia, including China

(63%), India (50%-70%), Nepal (>70%), Pakistan (urban area > 72%, rural area 98%), and Turkey (70%).<sup>80</sup>

Approximately 30 million people have epilepsy in the Asia-Oceania region, comprising a large proportion from the tropics,<sup>81</sup> that is, tropical Oceania has a high number of epilepsy patients. However, studies on PWE in tropical Oceania are scarce, unlike in Africa. Therefore, future studies should focus on these areas to fill the gap in

epilepsy diagnosis and treatment status quo in tropical Oceanian countries. We will also focus on the new results in this research area in the future.

In conclusion, the heavy burden of epilepsy varies globally and across tropical areas, which is related to the economic, cultural, and medical level of each region and country. The currently available data illustrated the relevance of epilepsy to the QoL and lifespan of the people in tropical countries, reflecting the negative impact of epilepsy and suggesting that more attention should be focused on the countries with a high burden of epilepsy.

## 2.3 | Risk factors

Available data have shown that the incidence of epilepsy is two to three times higher in tropical regions than in non-tropical industrialized countries.<sup>82</sup> The determination of the etiology of epilepsy is rather challenging. Due to their specific geographical location, climate environment, social environment, population distribution, and religious belief status, the determination of the etiology of epilepsy in tropical areas is complex and likely to include unidentified factors. Herein, we classified the etiology of epilepsy patients in tropical regions and summarized it as follows to provide a relevant reference for clinicians and researchers.

### 2.3.1 | Infectious agent

Due to the complex natural environment of tropical areas, viral infection is the most common cause of epileptic seizures. The causative viruses include malaria, HIV, cysticercosis, Zika virus, tuberculosis, Japanese encephalitis, West Nile virus, dengue fever, Nipah virus, and enterovirus. A community-based study in Nigeria, Tanzania, and Ethiopia found that only 10%-14% of patients had a specific etiology,<sup>77</sup> suggesting that the epilepsy etiology needs to be clarified further to provide an accurate direction and strategies for the treatment.

Parasitic infections associated with epilepsy are common in SSA, especially in areas with poor health.<sup>83</sup> In such areas, seizures occur in up to 90% of patients with active cysticercosis and in non-active cysticercosis with cerebral calcification. A population-based meta-analysis reported that a 10% increase in onchocerciasis is associated with an average 0.4% increase in the prevalence of epilepsy.<sup>77</sup> In Africa, differences in epilepsy were observed in onchocerciasis endemic areas. Generally, the epilepsy onset peaked around the age of 5-18 years, but in the onchocerciasis endemic areas, it peaked at the age of <5 years. Also, the incidence of epilepsy among children younger than 5 years increases with the rising

microfilariae load; also, Nods spasm and severe developmental delay are observed.<sup>84</sup>

In Mali, a West African region well-known for the malaria epidemic, exposure-nonexposure methods included 101 cases of cerebral malaria and 222 cases of asymptomatic type in children aged 0-15 years. According to the reported results, the risk of secondary epilepsy was higher in the cerebral malaria group than in asymptomatic malaria,<sup>85</sup> which illustrates that malaria has a major role in induced epilepsy. Moreover, a 2010 study in SSA in a tropical area showed that malaria affects about 174 million people or 81% of the global population, and diseases caused by *Plasmodium falciparum* and *Plasmodium vivax* malaria have been responsible for epileptic seizures in children in this region. At a hospital in Kenya, epilepsy was caused by malaria in 69% of hospitalized children.<sup>86</sup>

Another study conducted in Cameroon, a country in central and western Africa, showed a higher prevalence of epilepsy than in industrialized and other developing countries, and cysticercosis caused by *Taenia solium* infection was a major cause of epilepsy. In recent years, changes in the prevalence of epilepsy in Latin America have become obvious in countries with prevalent cysticercosis, resulting in a higher incidence compared to western countries and a prevalence that is inversely proportional to the per capita GDP of the country.<sup>87</sup>

However, whether antiparasitic drugs can improve seizures is yet controversial. Accumulating evidence suggests that treatment with antiparasitic drugs reduces the epileptic seizures in patients with parasitosis, at least by reducing the frequency of progression from focal epilepsy to bilateral convulsive seizures. Another study conducted in Uganda showed that ivermectin-treated onchocerciasis improved seizures in PWE. Moreover, in SSA, about 22.9 million people are living with HIV (57/100 million); a study has shown that 4%-17% of people living with HIV develop new seizures.<sup>88</sup>

### 2.3.2 | Perinatal illness

Unlike in adults, it is necessary to take the perinatal process seriously in infant patients with epilepsy. Infants and young children are likely to be affected by various factors during the perinatal period, resulting in epilepsy. For example, infectious diseases, including some vertically transmitted diseases, trauma during childbirth, intracranial ischemia, and hypoxia, affect the growth and development of the nervous system in newborns and infants. The effect causes the neurons in the brain to fire abnormally, leading to seizures. A previous study of children with epilepsy aged 0-18 years conducted in Burkina Faso, West Africa, 2016 showed that the average age of onset in 115 children included in the study was 8.2 years, and the

condition was predominant in males. This study aimed to statistically analyze the non-genetic factors related to the etiology of children with epilepsy. The results showed that perinatal events accounted for 79.1% of the risk factors in children with epilepsy. Brain sequelae of perinatal adverse events, central nervous system infection, and craniocerebral injury accounted for 34.8%, 14.8%, and 5.2%, respectively, which were the primary causes of non-hereditary epilepsy in children and adolescents.<sup>89</sup> Preterm birth is also associated with a high risk of seizures. According to a study that compared the status of epilepsy in Asia and Africa, preterm birth increased the risk of epilepsy five-fold. Among the top 10 countries with the highest number of preterm births, six are in Asia (India, China, Pakistan, Indonesia, Bangladesh, and the Philippines) and two in Africa (Nigeria and the Democratic Republic of the Congo).<sup>90</sup> Therefore, the non-genetic etiology of young children with epilepsy in tropical areas also deserves attention.

### 2.3.3 | Stroke

In tropical areas, some stroke patients suffer from post-stroke seizures (PSS), which affects the morbidity and mortality of PWE. A large multicenter study conducted in 15 hospitals across Nigeria and Ghana showed that PSS occurs in 499/3344 (14.9%) adults. A study that included selected stroke patients in Ghana also showed PSS in 1101 participants.<sup>91</sup> In another study, 126 patients exhibited post-stroke epilepsy (PSE).<sup>92</sup> These post-stroke seizures or seizures led to poor prognosis and posed a significant threat to the patient's nervous system, and even caused other health issues. Therefore, PSS affects the morbidity and mortality of PWE in tropical countries and poses a significant burden to tropical countries, especially those with low economic and medical levels.

### 2.3.4 | Head trauma

Typically, head trauma is a cause of epileptic seizures, but not the most common cause. However, the results of a case-control study in Nigeria and Kenya suggested that head injury is a major risk factor for PWE in this region,<sup>77</sup> which might be related to the social situation of some tropical countries. For example, in some African regions, traffic accidents frequently occur due to imperfect traffic laws and regulations, lack of relevant management, and indifferent safety awareness, thereby showing a prevalence of traumatic brain injury. In addition, social factors, such as injuries at work, personal fights, and wars, may increase the incidence of head trauma in the region.<sup>93</sup> Thus, the lack of neurosurgeons also aggravates the risk of head

trauma among patients, that is, a large number of people may suffer from head trauma and experience epilepsy as they cannot receive timely or appropriate treatment; this issue should be investigated further.

### 2.3.5 | Nutrition

Malnutrition is a perpetual global public health problem, and the correlation between malnutrition and epilepsy is a complicated issue. Due to economic constraints, a part of the population cannot afford proper nutrition needed for normal life activities in the majority of tropical countries. In infants and adolescents, as well as some adults, malnutrition causes growth deprivation of brain tissue in the stage of brain development, which tends to increase the susceptibility to epilepsy.<sup>94</sup> Also, the lack of nutrients in the body leads to low immune function and dysplasia of the nervous system, which can cause defects of the nervous system and induce the occurrence or aggravation of epilepsy. On the other hand, epilepsy may also lead to malnutrition. PWE use various drugs in the process of treatment or adhere to the ketogenic diet and other treatment methods. They may also suffer from secondary malnutrition, which aggravates the seizure of epilepsy. Usually, this vicious cycle has a significant impact on the prognosis. A study conducted in Benin showed that the prevalence of malnutrition in PWE (regardless of age) was about 22.1% (9.2% in the control group,  $P < 0.001$ ).<sup>95</sup> Another study based on a large demographic survey showed that the prevalence of malnutrition among children with epilepsy in Africa was about 25.4%.<sup>96</sup> Thus, malnutrition does affect epilepsy patients. However, as the onset of epilepsy may contribute to malnutrition, it should be considered in PWE, especially among children.

### 2.3.6 | Culture

The influence of different cultures and the infiltration of religious beliefs propagates a wrong perception of epilepsy in many tropical countries, which places PWE under psychological pressure or stigmatization. Because of the poor understanding of the condition, people do not treat it as a common disease but as some mysterious force on the human body. The consequences of such a wrong perception are very serious, as they can delay the optimal treatment opportunities for patients or completely deprive them of suitable treatment. A link was found between epilepsy and stunting in Ethiopia, raising the possibility of a link between early malnutrition and epilepsy in the tropics. On the other hand, there are some misunderstandings about the treatment of epilepsy. There

is no clear understanding of whether epilepsy can be treated by drugs, surgery, and other methods, which might delay the timely treatment of patients. These challenges are attributed to incomplete local publicity and lack of promotion of relevant education. For example, in Africa, most individuals do not think of epilepsy as a neurological disease but as a cultural, religious, or spiritual disease. Also, many people do not know that it can be treated with low-cost antiseizure medication (ASM) and that its onset can be controlled. This makes it difficult to improve the diagnosis and treatment of epilepsy in Africa. Some studies have shown that indigenous, Christian, and Islamic beliefs toward epilepsy in Africa have limited the development of relevant medicine in these areas, as these unscientific attitudes have prevented the African governments from providing adequate resources for the treatment, research, and training of medical professionals.<sup>76</sup>

### 2.3.7 | Genetics

In Africa, epilepsy was instigated by unclear causes in >60% of children,<sup>97</sup> suggesting that the influence of genetic factors in children with epilepsy should be emphasized in determining the etiology when excluding the perinatal factors.

In summary, there are various possibilities that could explain the etiology and inducement of PWE in tropical areas. The universality and particularity between tropical and non-tropical countries should be fully considered in the analysis and research of tropical countries. Specifically, the unique characteristics of tropical areas should be considered, including direct factors, such as the unique climate environment and pathogens, and indirect factors, such as social environment and resource problems. In addition to the factors mentioned above, it is also necessary to consider various indirect causes of epilepsy, such as brain tumors and immune system diseases. Understanding and analyzing the etiology of PWE in tropical areas from multiple angles might improve its diagnosis and treatment status.

## 3 | CHALLENGES AND INTERVENTIONS

### 3.1 | Professionalism and medical resources

Due to the low economic levels, most tropical countries suffer from a lack of medical resources, including shortage of medical equipment and drugs, insufficient medical

personnel, and a lack of specialist doctors and grassroots medical staff.

A survey showed that poor health facilities and inadequate training of health workers in Africa<sup>76</sup> are the primary reasons for the high prevalence and morbidity of epilepsy and the failure of timely diagnosis and treatment of PWE. Also, the relevant professionals in South Africa were inadequately trained and lacked compassion and respect.<sup>98</sup> This prompted negative emotions in PWE while receiving treatment, leading to or further aggravating stigma, in turn affecting their normal social activities and daily life. On the other hand, this phenomenon may give rise to negative feelings about the treatment, thus reducing treatment effectiveness and ultimately leading to a poor prognosis.

In addition, the issue of the shortage of medical personnel needs to be resolved urgently. According to one survey, Bhutan, a low- to middle-income country in Southeast Asia, has no neurologists in its public health care system.<sup>99</sup> In Italy, there is an average of one neurologist for every 5000 inhabitants, while in Malawi, there are only two neurologists for about 18.5 million inhabitants.<sup>100</sup> The lack of specialists not only strains the health resources of tropical countries but also undermines the health of their population. As epilepsy is a common chronic disease of the nervous system, long-term scientific diagnosis and treatment are the most critical means to promote the rehabilitation of patients. Therefore, tropical countries should focus on the shortage of specialists to ensure that local PWE receives timely diagnosis and treatment and has an improved QoL and prognosis.

### 3.2 | Comorbidity

In recent years, epilepsy comorbidity has become a global topic of interest. As a result, a large number of experts and scholars have focused on the problem of comorbidity in PWE. The current studies on epilepsy comorbidities, also in tropical countries, are mainly focused on mental diseases, such as epileptic comorbidities, anxiety, and depression.

The results of a meta-analysis showed that the prevalence of depression in PWE in SSA was about 32.71%, which is related to the local level of comprehensive treatment.<sup>101</sup> Due to insufficient medical resources, many patients with comorbid epilepsy cannot receive a treatment plan tailored to their individual situations. Some specialists ignore the patients' clinical manifestations and treatment needs due to the lack of awareness of comorbidities. In the Republic of Benin, a study of 196 subjects, aged >18 years, showed that PWE might be significantly associated with severe anxiety (79.8%) or



depression (89.6%) compared to normal controls (12.3% and 46.9%). Also, women were more likely to be affected than men.<sup>102</sup>

In conclusion, increasing evidence suggests that the role of comorbidity in the development of epilepsy should not be underestimated. The negative emotions of epilepsy comorbidity may have serious adverse effects on the QoL, including family and social life. Therefore, we urge the governments and medical institutions in tropical countries to focus on the comorbidities in PWE and promote their mental health for early recovery.

### 3.3 | Stigma and psychosocial environment

Unlike other prevalent chronic diseases, such as hypertension or coronary heart disease, a stigma is a common event with a high incidence among PWE. According to Weiss and Ramakrishna, health-related stigma is “a social process or related personal experience characterized by exclusion, rejection, blame, or devaluation that results from experience or reasonable anticipation of an adverse social judgment about a person or group identified with a particular health problem.”<sup>103</sup> Similarly, PWE who are frequently stigmatized may equally sustain such distress.

On average, stigma among PWE originates from the disease, the patient's sense of shame, and prejudice from the social environment. From the perspective of PWE, acute epileptic seizures that can occur at any time may give rise to a sense of shame to some extent. Furthermore, this unhealthy psychological state of PWE may increase with time, negatively affecting the patients' mental health and reducing their QoL.

Therefore, the factors leading to stigma among PWE are being investigated. Rice et al.<sup>104</sup> recruited a prospective cohort of PWE at the Lgnace Deen Hospital in Conakr, including 249 PWE (112 females and 137 males) and reported that “epilepsy stigma is more of a societal issue than a biological one.” In the study, the stigma scale of epilepsy (SSE) was regarded as the primary outcome measurement. The subjects had an average SSE score of 46.1 points (standard deviation = 14.5, the total score was 0–100). Based on the findings, it could be concluded that the frequency of seizures and depression level was positively associated, while household wealth was negatively associated with stigma, which was consistent with the multivariate analysis model.

Children are a special group of PWE and face multiple burdens. Many children with epilepsy are prevented from attending school in parts of Africa due to discrimination. Some of them are not allowed to eat with their families. Stigma also leaves these children with few or no childhood

friends, which might cause severe psychological damage that is difficult to heal.<sup>105,106</sup>

Currently, research on stigma among PWE is lacking, including large scientific and valid data as well as targeted analytical methods. Nonetheless, the psychological problems of PWE, except stigma, including depression or anxiety, have gained increasing attention in recent years.

In summary, PWE-associated stigma should be analyzed at multiple levels. As described above, it is a social problem and not only a medical condition. Consequently, a friendly psychosocial environment and a medical professional perspective have significant roles, which is time-consuming and arduous but crucial during this process.

### 3.4 | Policy and normative management

Being a chronic disease, strong policy preference and long-term standardized management are indispensable links in disease diagnosis and treatment for epilepsy. In this aspect, tropical countries have some shortcomings. For example, the public health system for epilepsy control is inadequate; policy is not yet implemented in most regions; lack of epilepsy-related chronic disease management methods and a complete treatment system, including the whole process from prevention and treatment to prognosis. Moreover, community hospitals and other basic medical service institutions have failed to provide the expected services; however, in recent years, many countries in the tropical region have been actively improving the medical environment for PWE.

Currently, there are 21 national epilepsy societies in Africa dealing with social issues and 14 national professional associations dealing with the scientific aspects of epilepsy. Initiatives already underway in Africa include establishing the Epilepsy Society, the Global Campaign Against Epilepsy (GCAE), and the Regional Congress. The Global Epilepsy Society in Africa has several achievements, including the declaration on Epilepsy in Africa, the establishment of new epilepsy societies in the region, and demonstration projects in Senegal and Zimbabwe. Other projects demonstrated that it is possible to manage epilepsy with limited resources. Increased health awareness among the population, availability of affordable medicines, and effective training of health workers are key components of successful epilepsy management.<sup>76</sup> In addition, the ongoing restructuring of the health system in South Africa has identified healthcare workers as a critical link in primary healthcare to ensure the sustainability of interventions and reduce the treatment gap for epilepsy in rural South Africa.<sup>41</sup> In resource-poor settings in rural Guinea-Bissau, local community rehabilitation services have bridged the gap in epilepsy treatment and improved

patient compliance. Furthermore, continuous clinical guidance for complicated cases improves the clinical treatment effect.<sup>107</sup> In Ghana, a new mental health bill was passed in 2012, which increased the allocation of health resources for mental disorders and epilepsy.<sup>77</sup> In response to the characteristics of tropical regions, many countries are actively improving their environmental health, undertaking malaria eradication activities, reducing transmission, and improving the control of tropical pathogens, such as cysticercosis, cystic echinococcosis, and onchocerciasis, and reducing the risk of infection.

SSA is known for the lack of transition from child care to adult care.<sup>77</sup> The problem might also exist in other tropical countries. Thus, we look forward to additional data that would allow professionals to develop prompt and reasonable solutions. Nonetheless, many countries in the tropical region are making efforts to improve the status of epilepsy treatment. Interventions at the government level are showing promising results. As a result, PWE in the tropics is expected to have better access to medical resources.

## 4 | CONCLUSION

In recent years, epilepsy has been understood rather clearly increasingly in most regions worldwide. For different types of epilepsy caused by different reasons, scientists and clinical workers are actively seeking effective treatment strategies and have made remarkable achievements. However, epilepsy has been a common chronic disease of the nervous system. Due to the lack of distinct regional characteristics, only a few individuals have explored its specificity in tropical areas. The current studies have shown that most tropical countries have a high incidence and prevalence of epilepsy,<sup>108,109</sup> a large number of PWE are not properly diagnosed and treated, and there may even be some undiagnosed PWE. This situation places a serious burden on the development of tropical countries. This phenomenon as the focus of the disease and the interests of the patients should be investigated further. First, for some patients who have not been formally diagnosed with epilepsy, due to neglect, cannot receive timely treatment, resulting in a poorer prognosis than in those who have the same condition but receive timely treatment; this affects the long-term QoL of patients and increases the burden of epilepsy diagnosis and treatment in tropical areas. Second, for patients who have been diagnosed with epilepsy, the etiology of the disease in tropical areas has not been fully explored, indirectly leading to the lack of targeted diagnosis and treatment strategy; thus, this subgroup of patients did not receive the correct treatment,

which would pose a threat to the long-term QoL of patients and accelerate the progress of the disease, forming a vicious cycle. Therefore, as a neglected perspective of epilepsy in tropical areas, there are many problems that have not been explored but cannot be ignored.

Therefore, in the face of various difficulties and challenges, there is a lot of work required to improve the economic level, improve the health policies and systems supported by the government and society, promote the allocation of medical resources, raise residents' health awareness, improve health conditions in tropical areas, popularize scientific knowledge, adopt effective prevention strategies, train grassroots medical staff, and form a standardized management system. The need to support the diagnosis and treatment of epilepsy in the tropics at the national and governmental level may help to create a favorable climate for PWE at the societal level and reduce the likelihood of comorbidities. At the technical level, relevant inspection and treatment equipment should be improved to ensure an adequate supply of ASM, improve the diagnosis and treatment level of medical personnel in tropical countries, and provide scientific and effective diagnosis and treatment plans for PWE.

From the clinical point of view, it is necessary to establish a systematic clinical management system for tropical epilepsy patients. As a chronic disease, accurate diagnosis and treatment alone cannot fundamentally solve the problem. Furthermore, it is necessary to popularize relevant knowledge for local people, use local cultural advantages, eliminate unscientific disease cognition, correctly understand the disease, prevent the occurrence of disease, and create a good social atmosphere under the premise of respecting different historical backgrounds, religious beliefs of various countries, and perspective of tertiary prevention, in the etiological prevention stage. In the pre-clinical prevention stage, various etiological and epidemiological studies can be carried out in different countries and regions to quickly, comprehensively, and emphatically improve the data bank of tropical epilepsy and improve the diagnosis and treatment level of epilepsy with tropical characteristics. This would achieve early detection, diagnosis, and treatment that might improve the prognosis and QoL of patients. Finally, in the stage of clinical prevention, apart from hiring a large number of professional doctors for treatment, an effective management system between the hospital and the community should be considered (regional management can be considered in some economically underdeveloped areas), family beds should be set up in local grassroots community hospitals, comprehensive management mode centering on epilepsy patients should be advocated, and long-term follow-up mechanism should be established. To carry out community rehabilitation,

improve the self-management level of patients, strengthen psychological guidance for patients, reduce the incidence of anxiety, depression, and other comorbidities of patients, and reduce the stigma of patients and their caregivers that would promote the mental health of patients and the recovery of the disease. In addition, there are special age groups of epilepsy patients in the tropics. For young children, attention should be focused on the problems of nutrition and genes; for women of childbearing age, attention should be focused on the management of pregnancy and perinatal period, including folic acid supplement. For the elderly population, the presence of other underlying diseases, such as epilepsy, that are neglected in the tropics, the interaction of multiple drugs, and the mental health, and QoL should be monitored closely.

Therefore, we hoped that additional studies on epilepsy patients in tropical countries would update or fill the data gaps. Moreover, in the process of formulating epilepsy management strategies, it is necessary to take into account the historical and cultural differences between different countries in tropical regions and the scientific nature of disease cognition, design respectful and reasonable clinical management policies, and improve the cooperation of patients and their families. Also, we must strive to provide practical and meaningful help for the health of PWE in tropical areas at the earliest.

## ACKNOWLEDGMENTS

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. We also thank the support of grants from the National Natural Science Foundation of China (81960249, 82260270), the Hainan Province Science and Technology Special Fund, Key Research and Development Project of Hainan Province (ZDYF2021SHFZ092, ZDYF2022SHFZ109), the Hainan Province Science and Technology Special Fund, Natural Science Foundation of Hainan Province (822RC832), and the Epilepsy Research Science Innovation Group of Hainan Medical University (2022), Hainan Province Clinical Medical Center (2021), and the Excellent Talent Team of Hainan Province (No.QRCBT202121). These figures were created by Biorender.

## CONFLICT OF INTEREST

The authors have declared that they have no competing interests

## ORCID

Jiaqi Liu  <https://orcid.org/0000-0003-2613-013X>  
 Shichuo Li  <https://orcid.org/0000-0002-8702-7489>  
 Jinmei Li  <https://orcid.org/0000-0002-7411-8269>

## REFERENCES

1. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):512–21.
2. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):522–30.
3. Huang H, Cui G, Tang H, Kong L, Wang X, Cui C, et al. Relationships between plasma expression levels of microRNA-146a and microRNA-132 in epileptic patients and their cognitive, mental and psychological disorders. *Bioengineered*. 2022;13(1):941–9.
4. Verrotti A, Carrozzino D, Milioni M, Minna M, Fulcheri M. Epilepsy and its main psychiatric comorbidities in adults and children. *J Neurol Sci*. 2014;343:23–9.
5. Otte WM, Nhaga AA, Tchuda DL, Abna B, van der Maas F. Cultural beliefs among people with epilepsy or physical impairment in Guinea-Bissau: differences and similarities. *Epilepsy Behav*. 2013;29(3):504–7.
6. Suryani G, Jehosua SY, Herlyani K, Zhi-Jien C, Kheng-Seang L. Attitudes toward epilepsy in Indonesia. *Epilepsy Behav*. 2021;123:108244.
7. Baum KT, Byars AW, de Grauw TJ, Johnson CS, Perkins SM, Dunn DW, et al. Temperament, family environment, and behavior problems in children with new-onset seizures. *Epilepsy Behav*. 2007;10(2):319–27.
8. Wilmshurst JM, Cross JH, Newton C, Kakooza AM, Wammanda RD, Mallewa M, et al. Children with epilepsy in Africa: recommendations from the international child neurology association/African child neurology association workshop. *J Child Neurol*. 2013;28(5):633–44.
9. Oguni H, Otsuki T, Kobayashi K, Inoue Y, Watanabe E, Sugai K, et al. Clinical analysis of catastrophic epilepsy in infancy and early childhood: results of the far-East Asia catastrophic epilepsy (FACE) study group. *Brain Dev*. 2013;35(8):786–92.
10. Assadek H, Toudou-Daouda M, Mamadou Z, Moussa-Konate M, Hassane-Djibo F, Douma-Maiga D. Clinical and etiological characteristics of epilepsy in the elderly: a hospital-based study from a tertiary care referral Center of Niamey, Niger. *J Neurosci Rural Pract*. 2019;10(4):571–5.
11. Bongomin F, Katabira E, Sajatovic M, Kaddumukasa M. Epilepsy in older people in sub-Saharan Africa: a systematic review. *Neuropsychiatr Dis Treat*. 2021;17:2309–14.
12. Colebunders R, Kaiser C, Basáñez MG, Olliaro P, Lakwo T, Siewe Fodjo JN. Reducing onchocerciasis-associated morbidity in onchocerciasis-endemic foci with high ongoing transmission: a focus on the children. *Int J Infect Dis*. 2022;116:302–5.
13. Tsega SS, Yazew BG, Mekonnen K. Sleep quality and associated factors among adult patients with epilepsy attending follow-up care at referral hospitals in Amhara region, Ethiopia. *PLoS One*. 2021;16(12):e0261386.
14. Kaddumukasa M, Kakooza A, Kayima J, Kaddumukasa MN, Ddumba E, Mugenyi L, et al. Community knowledge of and attitudes toward epilepsy in rural and urban Mukono district, Uganda: a cross-sectional study. *Epilepsy Behav*. 2016;54:7–11.

15. Joshua SP, Mahapatra AK. Epilepsy in tropics: Indian perspective. *J Neurosci Rural Pract.* 2013;4(2):171–5.
16. Zheng G, Li F, Chen Y, Liu H, Wang S, Lao J, et al. An epidemiological survey of epilepsy in tropical rural areas of China. *Epilepsia Open.* 2021;6(2):323–30.
17. Quet F, Rafael F, Ngougou EB, Diagana M, Druet-Cabanac M, Preux PM. Investigating epilepsy in Africa: 10 years of data collection using a standardized questionnaire in 2,269 peoples with epilepsy[J]. *Epilepsia.* 2011;52(10):1868–76.
18. Gilkinson C, Kinney M, Olaniyan T, Murtala B, Sipilon M, Malunga A, et al. Perceptions about mental healthcare for people with epilepsy in Africa. *Epilepsy Behav.* 2022;127:108504.
19. Bruno E, Bartoloni A, Zammarchi L, Strohmeyer M, Bartalesi F, Bustos JA, et al. Epilepsy and neurocysticercosis in Latin America: a systematic review and meta-analysis. *PLoS Negl Trop Dis.* 2013;7(10):e2480.
20. Medina MT, Durón RM, Martínez L, Osorio JR, Estrada A, Zúniga C, et al. Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salamá study. *Epilepsia.* 2005;46(1):124–31.
21. Mond C, Duke T, Vince J. Epilepsy in Papua New Guinea: a longitudinal cohort study. *Arch Dis Child.* 2019;104(10):941–6.
22. OPL136 indigenous and remote epilepsy in tropical Australia. *J Neurol Sci.* 2005;238(S1):S80–1.
23. Deresse B, Shaweno D. General public knowledge, attitudes, and practices towards persons with epilepsy in South Ethiopia: a comparative community-based cross-sectional study. *Epilepsy Behav.* 2016;58:106–10.
24. Mbelesso P, Luna J, Yangatimbi E, Mboukou C, Preux PM. Sociocultural representations of epilepsy in the Central African Republic: a door-to-door survey[J]. *Seizure.* 2019;67:23–6.
25. Molla A, Mekuriaw B, Habtamu E, Mareg M. Knowledge and attitude towards epilepsy among rural residents in Southern Ethiopia: a cross-sectional study. *BMC Public Health.* 2021;21(1):420.
26. Muchada IF, Wilmshurst JM, Laing N, Haf Davies E, Fieggen K. A qualitative study exploring caregivers' experiences, perspectives, and expectations for precision medicine in epilepsy in South Africa. *Epilepsy Behav.* 2021;117:107873.
27. Sengxeu N, Dufat H, Boumediene F, Vorachit S, Chivorakoun P, Souvong V, et al. Availability, affordability, and quality of essential antiepileptic drugs in Lao PDR. *Epilepsia Open.* 2020;5(4):550–61.
28. Owolabi LF, Owolabi SD, Adamu B, Jibo AM, Alhaji ID. Epilepsy treatment gap in sub-Saharan Africa: meta-analysis of community-based studies. *Acta Neurol Scand.* 2020;142(1):3–13.
29. Chin JH. Epilepsy treatment in sub-Saharan Africa: closing the gap. *Afr Health Sci.* 2012;12(2):186–92.
30. Winkler AS. Measuring the epilepsy treatment gap in sub-Saharan Africa. *Lancet Neurol.* 2012;11(8):655–7.
31. Nau AL, Mwape KE, Wiefek J, Schmidt K, Abatih E, Dorny P, et al. Cognitive impairment and quality of life of people with epilepsy and neurocysticercosis in Zambia. *Epilepsy Behav.* 2018;80:354–9.
32. Nsengiyumva G, Druet-Cabanac M, Ramanankandrasana B, Bouteille B, Nsibabira L, Preux PM. Cysticercosis as a major risk factor for epilepsy in Burundi, East Africa[J]. *Epilepsia.* 2003;44(7):950–5.
33. Elliott I, Jerome A, Angwafor SA, Smith ML, Takougang I, Noh J, et al. Epilepsy and cysticercosis in Northwest Cameroon: a serological study. *Seizure.* 2013;22(4):283–6.
34. Winkler AS, Willingham AL 3rd, Sikasunge CS, Schmutzhard E. Epilepsy and neurocysticercosis in sub-Saharan Africa. *Wien Klin Wochenschr.* 2009;121(Suppl 3):3–12.
35. Sahlu I, Carabin H, Ganaba R, Preux PM, Cissé AK, Tarnagda Z, et al. Estimating the association between being seropositive for cysticercosis and the prevalence of epilepsy and severe chronic headaches in 60 villages of rural Burkina Faso. *PLoS Negl Trop Dis.* 2019;13(1):e0007101.
36. Carrizosa Moog J, Kakooza-Mwesige A, Tan CT. Epilepsy in the tropics: emerging etiologies. *Seizure.* 2017;44:108–12.
37. Pacheco-Barrios K, Cardenas-Rojas A, Alva-Diaz C. Burden of disease due to epilepsy in Latin America: a systematic analysis of the global burden disease study 2017. *J Neurol Sci.* 2019;405:39.
38. Quet F, Preux PM, Huerta M, Ramirez R, Abad T, Fragoso G, et al. Determining the burden of neurological disorders in populations living in tropical areas: who would be questioned? Lessons from a Mexican rural community. *Neuroepidemiology.* 2011;36(3):194–203.
39. Wibecan L, Fink G, Tshering L, Bruno V, Patenaude B, Nirola DK, et al. The economic burden of epilepsy in Bhutan. *Trop Med Int Health.* 2018;23(4):342–58.
40. Burneo JG, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence[J]. *Epilepsy Res.* 2005;66(1–3):63–74.
41. Wagner RG, Norström F, Bertram MY, Tollman S, Forsgren L, Newton CR, et al. Community health workers to improve adherence to anti-seizure medication in rural South Africa: is it cost-effective?[J]. *Epilepsia.* 2021;62(1):98–106.
42. Adebisi A, Lagunju I, Ogunniyi A. Epilepsy in transition from child care to adult service: a missing link in sub-Saharan Africa. *Trop Doct.* 2017;47(3):273–5.
43. Nkole KL, Kawatu N, Patel AA, Kanyinji C, Njobvu T, Chipeta J, et al. Ketogenic diet in Zambia: managing drug-resistant epilepsy in a low and middle income country. *Epilepsy Behav Rep.* 2020;14:100380.
44. Acevedo C. Latin America's strategic plan for prevention and care of epilepsy. *J Neurol Sci.* 2015;357(S1):e503.
45. Epilepsy: a public health imperative. WHO/MSD/MER/19.2.
46. Fawi G, Khedr EM, El-Fetoh NA, Thabit MN, Abbass MA, Zaki AF. Community-based epidemiological study of epilepsy in the Qena governorate in upper Egypt, a door-to-door survey. *Epilepsy Res.* 2015;113:68–75.
47. Winkler AS, Kerschbaumsteiner K, Stelzhammer B, Meindl M, Kaaya J, Schmutzhard E. Prevalence, incidence, and clinical characteristics of epilepsy: a community-based door-to-door study in northern Tanzania. *Epilepsia.* 2009;50(10):2310–3.
48. Tekle-Haimanot R, Forsgren L, Ekstedt J. Incidence of epilepsy in rural Central Ethiopia. *Epilepsia.* 1997;38(5):541–6.
49. Yazie TS, Kefale B, Molla M. Treatment outcome of epileptic patients receiving antiepileptic drugs in Ethiopia: a systematic review and meta-analysis. *Behav Neurol.* 2021;5586041. <https://doi.org/10.1155/2021/5586041>
50. Houinato D, Yemadje LP, Glitho GA, Adjien C, Avode G, Druet-Cabanac M, et al. Epidemiology of epilepsy in rural Benin: prevalence, incidence, mortality, and follow-up. *Epilepsia.* 2013;54(4):757–63.

51. Kariuki SM, Chengo E, Ibinda F, Odhiambo R, Etyang A, Ngugi AK, et al. Burden, causes, and outcomes of people with epilepsy admitted to a rural hospital in Kenya. *Epilepsia*. 2015;56(4):577–84.
52. Birbeck GL, Kalichi EM. Epilepsy prevalence in rural Zambia: a door-to-door survey[J]. *Trop Med Int Health*. 2004;9(1):92–5.
53. Nwani PO, Nwosu MC, Asomugha LA, Enwereji KO, Arinzechio EO, Ogunniyi AO. Epidemiology of active epilepsy in a suburban community in Southeast Nigeria: a door-to-door survey. *Niger J Clin Pract*. 2015;18(4):527–33.
54. Dedeken P, Sebera F, Mutungirehe S, Garrez I, Umwiringirwa J, van Steenkiste F, et al. High prevalence of epilepsy in northern Rwanda: exploring gender differences. *Brain Behav*. 2021;11(11):e2377.
55. Ray BK, Bhattacharya S, Kundu TN, Saha SP, Das SK. Epidemiology of epilepsy--Indian perspective. *J Indian Med Assoc*. 2002;100(5):322–6.
56. Fong GC, Mak W, Cheng TS, Chan KH, Fong JK, Ho SL. A prevalence study of epilepsy in Hong Kong. *Hong Kong Med J*. 2003;9(4):252–7.
57. Chou I-J, Chung T-T, Liu Y-H, Hung P-C, Lin J-J, Chiou M-J, et al. Secular trends in the incidence, prevalence, and medications for epilepsy from 2007 to 2015 in Taiwan: a nationwide population-based study. *Neuroepidemiology*. 2021;55:484–94.
58. Yu ZP, Tang YX, Wang WM. An epidemiological survey of epilepsy among Wa nationality in Yunnan, China. *Chinese J Epidemiol*. 2009;1:95–6.
59. Yu Z, Dong K, Chang H, Huang XQ, Ren Y, Fan CQ, et al. The epidemiological and clinical characteristics study on epilepsy in 8 ethnic groups of China. *Epilepsy Res*. 2017;138:110–5.
60. Zheng GX, Li FT, Chen YM, Liu HJ, Wang SR, Lao JT, et al. An epidemiological survey of epilepsy in rural and minority areas of China. *Chinese Journal of Neurosurg*. 1985;5(S1):24–30.
61. Loh NK, Lee WL, Yew WW, Tjia TL. Refractory seizures in a young army cohort. *Ann Acad Med Singapore*. 1997;26(4):471–4.
62. Tran DS, Odermatt P, Le TO, Huc P, Druet-Cabanac M, Barennes H, et al. Prevalence of epilepsy in a rural district of central Lao PDR. *Neuroepidemiology*. 2006;26(4):199–206.
63. Asawavichienjinda T, Sitthi-Amorn C, Tanyanont W. Prevalence of epilepsy in rural Thailand: a population-based study. *J Med Assoc Thai*. 2002;85(10):1066–73.
64. Hun C, Hok T, Ros S, Chan S, Bhalla D. Epilepsy: some controversies, some knowledge and some experience from Cambodia. *Neurol India*. 2014;62(6):606–9.
65. Lavados J, Germain L, Morales A, Campero M, Lavados P. A descriptive study of epilepsy in the district of El Salvador, Chile, 1984–1988. *Acta Neurol Scand*. 1992;85(4):249–56.
66. Placencia M, Shorvon SD, Paredes V, Bimos C, Sander JW, Suarez J, et al. Epileptic seizures in an Andean region of Ecuador. Incidence and prevalence and regional variation. *Brain*. 1992;115(Pt 3):771–82.
67. Carpio A, Bharucha NE, Jallon P, Beghi E, Camprostrini R, Zorzetto S, et al. Mortality of epilepsy in developing countries[J]. *Epilepsia*. 2005;46(Suppl 11):28–32.
68. Jallon P, Smadja D, Cabre P, Mab G, Bazin M, EPIMART. EPIMART: prospective incidence study of epileptic seizures in newly referred patients in a French Caribbean Island (Martinique). *Epilepsia*. 1999;40(8):1103–9.
69. Medina M, Molina L, Duron R, Hesse H, Su H, Zelaya A, et al. Prevalence of epilepsy in Honduras: a national population based-study. *Epilepsia*. 2003;44(8):155.
70. Medina MT, Duron RM, Martinez L, Osorio JR, Estrada AL, Zuniga C, et al. Prevalence, incidence, and etiology of epilepsies in rural Honduras: the Salama study. *Epilpsia*. 2005;46(1):124–31.
71. Gracia FJ, Bayard V, Triana E, Castillo LC, Benzadón A, Larreátegui M, et al. Prevalence of neurologic diseases in Belisario Porras municipality, district of San Miguelito, Panama, 1986. *Rev Med Panama*. 1988;13(1):40–5.
72. Patel AP, Fisher JL, Nichols E, Abd-Allah F, Abdela J, Abdelalim A, et al. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the global burden of disease study 2016[J]. *Lancet Neurol*. 2019;18(4):357–75.
73. WHA68.20 Resolution, 2015.
74. Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. *Epilepsia*. 2010;51(5):883–90.
75. Tucker L. Challenges and opportunities in the prevention and treatment of epilepsy in Africa: perspectives from across the continent. *J Neurol Sci*. 2019;405:79.
76. Mugumbate J, Zimba AM. Epilepsy in Africa: past, present, and future. *Epilepsy Behav*. 2018;79:239–41.
77. Prevett M. Epilepsy in sub-Saharan Africa. *Pract Neurol*. 2013;13(1):14–20.
78. Declaration of Santiago on epilepsy in Latin America. *Epilepsia*. 2002;43(Suppl 6):42.
79. Bhalla D, Samleng C, Gérard D, Oum S, Druet-Cabanac M, Preux PM. Epilepsy in Asia: a Cambodian experience. *Neuroepidemiology*. 2013;40(4):260–3.
80. Mac TL, Tran DS, Quet F, Odermatt P, Preux PM, Tan CT. Epidemiology, aetiology, and clinical management of epilepsy in Asia: a systematic review. *Lancet Neurol*. 2007;6(6):533–43.
81. Kwan P, Cabral-Lim L, D'Souza W, Jain S, Lee BI, Liao W, et al. Research priorities in epilepsy for the Asia-Oceanian region. *Epilepsia*. 2015;56(5):667–73.
82. Ngougou EB, Quet F, Dubreuil CM, Marin B, Houinato D, Nubukpo P, et al. Epidémiologie de l'épilepsie en Afrique subsaharienne: une revue de la littérature [Epidemiology of epilepsy in sub-Saharan Africa: a review]. *Sante*. 2006;16(4):225–38.
83. Mazigo HD, Morona D, Kweka EJ, Waihenya R, Mnyone L, Heukelbach J. Epilepsy and tropical parasitic infections in sub-Saharan Africa: a review. *Tanzan J Health Res*. 2013;15(2):102–19.
84. Colebunders R, Hotterbeekx A, Siewe J, Mandro M, Mbonye M, Suykerbuyk P. Epilepsy caused by onchocerciasis is an important public health problem in Africa. *Int J Infect Dis*. 2018;73:316–7.
85. Ngougou EB, Dulac O, Poudiougou B, Druet-Cabanac M, Dicko A, Mamadou Traore A, et al. Epilepsy as a consequence of cerebral malaria in area in which malaria is endemic in Mali, West Africa. *Epilepsia*. 2006;47(5):873–9.
86. Waruiru CM, Newton CR, Forster D, New L, Winstanley P, Mwangi I, et al. Epileptic seizures and malaria in Kenyan children. *Trans R Soc Trop Med Hyg*. 1996;90(2):152–5.
87. Garcia-Martin G, Serrano-Castro PJ. Epidemiología de la epilepsia en España y Latinoamérica [Epidemiology of epilepsy in Spain and Latin America]. *Rev Neurol*. 2018;67(7):249–62.

88. Leone M, Ciccacci F, Orlando S, Petrolati S, Guidotti G, Majid NA, et al. Pandemics and burden of stroke and epilepsy in sub-Saharan Africa: experience from a longstanding health Programme. *Int J Environ Res Public Health*. 2021;18(5):2766.
89. Lompo DL, Diallo O, Dao BA, Bassole R, Napon C, Kabore J. Etiologies of non-genetic epilepsies of child and adolescent, newly diagnosed in Ouagadougou, Burkina Faso. *Pan Afr Med J*. 2018;31:175.
90. Bhalla D, Tchalla AE, Marin B, Ngougou EB, Tan CT, Preux PM. Epilepsy: Asia versus Africa. *Epilepsia*. 2014;55(9):1317–21.
91. Sarfo FS, Akinyemi J, Akpalu A, Wahab K, Yaria J, Adebayo O, et al. Frequency and factors associated with post-stroke seizures in a large multicenter study in West Africa. *J Neurol Sci*. 2021;427:117535.
92. Sarfo FS, Akassi J, Obese V, Adamu S, Agbenorku M, Ovbiagele B. Prevalence and predictors of post-stroke epilepsy among Ghanaian stroke survivors. *J Neurol Sci*. 2020;418:117138.
93. Preux PM, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. *Lancet Neurol*. 2005;4(1):21–31.
94. Crepin S, Godet B, Chassain B, Preux PM, Desport JC. Malnutrition and epilepsy: a two-way relationship. *Clini Nutr (Edinburgh, Scotland)*. 2009;28(3):219–25.
95. Crepin S, Houinato D, Nawana B, Avode GD, Preux PM, Desport JC. Link between epilepsy and malnutrition in a rural area of Benin. *Epilepsia*. 2007;48(10):1926–33.
96. F Quet, F Dalmay, Marin B, Michel Druet-Cabanac. Limoges, questionnaire for investigating epilepsy: one decade and prospects from an analysis of 2,313 questionnaire from Africa. 2005.
97. Esterhuizen AI, Carvill GL, Ramesar RS, Kariuki SM, Newton CR, Poduri A, et al. Clinical application of epilepsy genetics in Africa: is now the time? *Front Neurol*. 2018;9:276.
98. Keikelame MJ, Swartz L. "The others look at you as if you are a grave": a qualitative study of subjective experiences of patients with epilepsy regarding their treatment and care in Cape Town, South Africa. *BMC Int Health Hum Rights*. 2016;16:9.
99. Stauder M, Vogel AC, Nirola DK, Tshering L, Dema U, Dorji C, et al. Depression, sleep quality, and social isolation among people with epilepsy in Bhutan: a cross-sectional study. *Epilepsy Behav*. 2020;112:107450.
100. Leone M, Marazzi MC, Tolno VT, Tedeschi G, Mancardi G. Epilepsy in sub-Saharan Africa: is there anything neurologists could learn from HIV/AIDS health care? *Neurological Sci*. 2020;41(11):3341–3.
101. Dessie G, Mulugeta H, Leshargie CT, Wagnew F, Burrowes S. Depression among epileptic patients and its association with drug therapy in sub-Saharan Africa: a systematic review and meta-analysis. *PLoS One*. 2019;14(3):e0202613.
102. Nubukpo P, Houinato D, Preux PM, Avodé G, Clément JP. Anxiété et dépression chez les épileptiques en population générale au Bénin (Afrique de l'Ouest) [Anxiety and depression among the epileptics in general population in Benin (Western Africa)]. *L'Encephale*. 2004;30(3):214–9.
103. Weiss MG, Ramakrishna J. Stigma interventions and research for international health. *Lancet*. 2006;367(9509):536–8.
104. Rice DR, Cisse FA, Hamani ABD, Tassiou NR, Sakadi F, Bah AK, et al. Epilepsy stigma in the Republic of Guinea and its socioeconomic and clinical associations: a cross-sectional analysis. *Epilepsy Res*. 2021;177:106770.
105. Boling W, Means M, Fletcher A. Quality of life and stigma in epilepsy, perspectives from selected regions of Asia and sub-Saharan Africa. *Brain Sci*. 2018;8(4):59.
106. Matuja WB, Rwiza HT. Knowledge, attitude and practice (KAP) towards epilepsy in secondary school students in Tanzania. *Cent Afr J Med*. 1994;40(1):13–8.
107. van Diessen E, van der Maas F, Cabral V, Otte WM. Community-based rehabilitation offers cost-effective epilepsy treatment in rural Guinea-Bissau. *Epilepsy Behav*. 2018;79:23–5.
108. Devi KR, Borbora D, Upadhyay N, Goswami D, Rajguru SK, Narain K. Neurocysticercosis in patients with active epilepsy in the tea garden community of Assam, Northeast India. *Sci Rep*. 2021;11(1):7433.
109. Levick B, Laudisoit A, Tepage F, Ensoy-Musoro C, Mandro M, Bonareri Osoro C, et al. High prevalence of epilepsy in onchocerciasis endemic regions in The Democratic Republic of the Congo. *PLoS Negl Trop Dis*. 2017;11(7):e0005732.

**How to cite this article:** Liu J, Zhang P, Zou Q, Liang J, Chen Y, Cai Y, et al. Status of epilepsy in the tropics: An overlooked perspective. *Epilepsia Open*. 2023;8:32–45. <https://doi.org/10.1002/epi4.12686>